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Abstract
Dual antiplatelet therapy is currently recommended for all patients with acute coronary syn-
dromes, independent of whether they receive pharmacological treatment or undergo percutane-
ous coronary intervention. Antiplatelet agents are the cornerstone of pharmacological treat-
ment in interventional cardiology. However, there is a clear need for randomized trials to
assess the treatment strategy of dual antiplatelet therapy in patients who also need long-term
antithrombotic treatment (such as those with atrial fibrillation, prosthetic heart valve, mitral
valve regurgitation or stenosis, deep vein thrombosis, pulmonary embolism, or pulmonary
hypertension). In this paper we discuss trials and analyses on the use of dual antiplatelet
treatment in combination with antithrombotic therapy in particular diseases, with a focus on
the risk of hemorrhagic events connected with this treatment, as well as recent guidelines of the
European Society of Cardiology, the American College of Cardiology, and the American Heart
Association. (Cardiol J 2009; 16, 2: 179–189)
Key words: antiplatelet therapy, antithrombotic treatment, acetylsalicylic acid,
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Introduction
The need for simultaneous dual antiplatelet and
oral anticoagulant (OAC) therapy is increasing. Dual
antiplatelet therapy is currently recommended for
all patients with acute coronary syndromes (ACS),
independent of whether the patients are treated
pharmacologically or with percutaneous coronary
interventions (PCI) [1, 2]. Antiplatelet agents are
the cornerstone of pharmacological treatment in in-
terventional cardiology. Their use is necessary
owing to the activation of platelets caused by dama-
ge to the endothelium and deeper layers of the ves-
sel during percutaneous coronary intervention [3].
The number of patients of advanced age with
ACS is increasing as life expectancy increases [4].
These patients are also more often diagnosed with
atrial fibrillation (AF). Age greater than 75 years is an
important risk factor for thromboembolic events, but
also increases the risk of hemorrhagic complications.
Many trials have shown that antiplatelet therapy with
acetylsalicylic acid (ASA) and clopidogrel is less ef-
fective than OAC therapy for the prevention of stro-
ke, myocardial infarction (MI), or peripheral embolism
in patients with AF and at high risk of thromboembo-
lic events [5, 6]. On the other hand, oral anticoagula-
tion alone is not recommended in patients who have
undergone a coronary stent procedure, because it is
associated with a 50% increased risk of death or MI
caused by subacute embolism in stents [7, 8].
There is still a lack of data from large rando-
mized trials to determine the best strategies for
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therapeutic management of patients with indica-
tions for dual antiplatelet therapy and for long-term
antithrombotic treatment such as AF, prosthetic
heart valves, thrombus in the left ventricle, or ve-
nous thrombotic disease. Use of dual antiplatelet
therapy in ACS patients with simultaneous indica-
tions for OAC therapy seems reasonable, although
the statements from cardiology societies are not
unequivocal.
Acute coronary syndromes
The degree of vessel stenosis caused by athe-
rosclerotic lesions is not thought to play a major role
in the pathophysiology of ACS. Instability of the
atherosclerotic lesion, inflammatory processes, and
thrombotic factors are now considered the main
causes of ACS that determine the risk of thrombus
formation on rupturing or ruptured lesions [4].
Damage of the vascular wall, resulting from the
rupture of unstable atherosclerotic lesions (70% of
ACS) or ulceration of critical lesions, makes the
adhesion, activation, and aggregation of platelets
possible, which in turn results in thrombus forma-
tion and regional decreases in blood flow with re-
duced tissue perfusion [9]. Acute thrombosis is
often accompanied by vessel spasm, which further
limits the flow of blood. During ST elevation myo-
cardial infarction (STEMI), a thrombus rich in fibrin,
causes total occlusion of the vessel. In patients pre-
senting with non-ST elevation acute coronary syn-
drome (NSTE-ACS), the thrombus is rich in plate-
lets and causes partial or total, but short-lasting, oc-
clusion. Thrombi rich in platelets can break down
into small pieces, and translocation in the blood can
cause embolism of small arteries or capillary ves-
sels. This process leads to small areas of myocar-
dial necrosis and increased levels of markers of my-
ocardial necrosis [10, 11]. The goal of antiplatelet
treatment in NSTE-ACS is the disruption of throm-
bi rich in platelets, stabilization of atherosclerotic
lesions and prevention of total vessel occlusion.
Therapeutic management in STEMI is focused on
restoration of blood flow in infarcted arteries.
Discovery of markers of thrombin formation
and platelet activation, and demonstration of the
benefits of antithrombotic treatment have contri-
buted to a better understanding of the role of throm-
bosis in ACS [12]. Trials in patients with coronary
artery disease have shown that use of OACs, with
international normalized ratio (INR) level greater
than 2, in combination with ASA significantly redu-
ces total mortality and the incidence rates of MI and
stroke, but is also associated with an increased risk
of hemorrhagic complications compared with ASA
alone [13–19]. Compared with ASA alone, the combi-
nation of ASA and OAC, with INR level less than 2,
is not beneficial in preventing ischemic events,
but increases the risk of hemorrhagic complications
[18, 20, 21].
The process of platelet activation should be
considered not only as acute rupture of atheroscle-
rotic lesions but also as a factor that increases the
risk of recurrent events due to atherosclerosis in
patients with inflammatory processes in the vessel
wall and systemic circulation. The duration of this
increased risk after ACS is unknown. It is known
that the processes mentioned above play important
roles in the recurrence of acute ischemic incidents,
which is why antiplatelet treatment is crucial du-
ring ACS and as chronic supportive therapy [2, 22–
–24]. Dual antiplatelet therapy with ASA and clopi-
dogrel after PCI is superior to therapy with ASA
[25, 26] or warfarin alone or the combination of ASA
and warfarin [8, 25, 27]. The addition of clopidogrel
to ASA significantly reduces the risk of recurrent
MI and angiovascular mortality in patients with ACS
[26]. Dual antiplatelet therapy is particularly impor-
tant after implantation of drug-eluting stents (DES),
the use of which is associated with an increased risk
of late stent thrombosis compared to bare metal
stents (BMS). According to the European Society
of Cardiology (ESC) and American College of Car-
diology/American Heart Association/Society for
Coronary Angiography and Interventions (ACC/
/AHA/SCAI) guidelines for PCI [3, 28] and the use
of anticoagulants in heart disease [29], it is reaso-
nable to avoid DES and use BMS as a safer option
in patients requiring concomitant therapy with ASA,
clopidogrel, and OAC.
Atrial fibrillation
Atrial fibrillation is the most common indication
for chronic antithrombotic therapy. It occurs in about
5–20% of patients with ACS. Some of these patients
present with AF before ACS. In others, it is a conse-
quence of the acute phase of ACS, which results in
further poor prognosis. There are a few reasons for
the coexistence of ACS and AF: both AF and ACS are
common in patients of advanced age; dysfunction of
the left ventricle, metabolic processes, inflammato-
ry reaction of the pericardium, increased levels of
catecholamines, or use of drugs stimulating beta re-
ceptors are factors that occur in ACS and can cause
AF; and infarction or ischemia of the atria directly
increases muscular excitability of the atria, thereby
predisposing it to manifestation of arrhythmia.
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Trials performed before [30–36] and after the
era of fibrinolytic therapy [37, 38] showed that
mortality in patients with both ACS and AF is two
times greater compared with the population witho-
ut AF [39–42]. One-year observational studies in
patients with AF and ACS who were treated with
invasive procedures clearly show that AF is an in-
dependent risk factor and increases mortality. It has
also been shown that PCI is associated with a re-
duced rate of AF occurrence compared with throm-
bolysis [40]. The GUSTO study showed that pa-
tients with AF presented with more intense athe-
rosclerosis of the coronary arteries and poorer
reperfusion of infarcted vessels. Three-vessel dise-
ase and reduced ejection fraction of the left ventric-
le were more common in these patients, and they
are at increased risk of in-hospital complications such
as recurrent MI or ischemic events, heart failure,
cardiogenic shock, ventricular arrhythmias, distur-
bances of atrioventricular conduction, acute mitral
regurgitation, rupture of the interventricular septum,
or systemic thrombosis. Patients with persistent AF
were at increased risk of cerebrovascular events than
patients with sinus rhythm [41, 37].
Overview of studies on simultaneous
use of dual antiplatelet therapy and
antithrombotic therapy
Previous analyses have shown great variabili-
ty in the regimens used in patients with indications
for concomitant dual antiplatelet therapy and OAC
(triple therapy).
Lip et al. [43] performed a retrospective ana-
lysis of 1,234 patients who had undergone PCI,
35 of whom presented AF. At the time of hospital
admission, 19 of these 35 patients had pre-existing
AF, 11 patients were receiving warfarin, 5 aspirin,
2 clopidogrel, and 1 patient was receiving no anti-
thrombotic therapy. All patients receiving OAC had
it discontinued prior to PCI and 65.7% were treated
with low-molecular-weight heparin in addition to
ASA and clopidogrel. At discharge from hospital,
dual antiplatelet therapy was prescribed to 71.4%
of patients, whereas 6 patients received triple the-
rapy (17.1%), 2 received clopidogrel (5.7%), and
2 received warfarin plus one antiplatelet drug
(5.7%). Further ambulatory management was he-
terogeneous: 10 patients were administered 1-year
clopidogrel treatment plus lifelong ASA, 4 patients
were treated with lifelong ASA and clopidogrel, and
8 patients were told to stop one of their antiplate-
let drugs and replace it with warfarin. The use of
triple therapy is relatively low owing to concerns
of life-threatening bleeding. There were no bleeding
complications requiring hospitalization after 30 days
of follow-up.
In the study conducted by Karjalainen et al. [44],
239 patients with an indication for long-term OAC
[such as AF, prosthetic heart valve, prior venous
thrombotic disease (VTD)] treated with PCI were
identified. Persistent AF was the most common in-
dication for OAC treatment (70%). DESs were im-
planted in 40% of patients. The mean INR value was
2.19 ± 0.54 on the day of PCI. After coronary sten-
ting, 48.4% of patients received triple therapy.
A total of 15.5% of patients switched from warfarin
to dual antiplatelet therapy with ASA and clopido-
grel, 15.1% received warfarin and ASA, and 0.5%
received warfarin alone. The duration of clopidogrel
treatment was significantly shorter in the triple the-
rapy group (about 4.14 months) but longer in pa-
tients receiving DES (5.88 months) than in patients
with BMS (4.09 months). During the follow-up pe-
riod, stent thrombosis (15.2%) or MI (18.2%) oc-
curred in patients not receiving clopidogrel, and
there was an increased risk of stroke in the group
not receiving warfarin. Bleeding complications were
most common with triple therapy or the combina-
tion of warfarin and clopidogrel; intracranial ble-
eding occurred in 3 patients, gastrointestinal events
in 2, groin hematoma in 4, retroperitoneal bleeding
in 1, urinary bleeding in 1, and a decrease in blood
hemoglobin level (4 g/dL) in 17 patients. These data
support the view that triple therapy is an optimal
therapeutic option in patients who have undergone
PCI and have indications for OAC.
In a prospective analysis that included 70 patients
who had undergone coronary stenting and were re-
ceiving long-term anticoagulation therapy, the effec-
tive treatment prescribed on discharge from hospital
was triple therapy in 64.2% of patients, ASA plus clo-
pidogrel in 25.4%, and OAC plus clopidogrel in 3%.
Withdrawal of dual antiplatelet therapy within 1 year
was common in all patients groups, but was more
marked for clopidogrel, which was prescribed to 92.3%
of patients in the first month and to 43.5% 1 year after
PCI. The overall percentage of patients who received
triple therapy was 55.4% in the first month, 32.8% in
the sixth month, and 16.9% at 1 year after PCI. Only
half of the patients who underwent DES implantation
continued with dual antiplatelet therapy 6 months
after the procedure. Triple therapy has been shown
to be an independent predictor of major bleeding risk,
associated with a 5-fold increase in risk compared with
dual antiplatelet therapy [45].
In a study including 426 patients who had
undergone PCI with paroxysmal (39.9%) and
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permanent (60.1%) AF, triple therapy was most
often prescribed in the group with persistent AF
(55.8%), compared with those with paroxysmal AF,
for whom dual antiplatelet therapy was most com-
mon (49.5%). A lack of treatment with coumarins
and advanced age were independent predictors of
MI and target coronary revascularization [46].
Despite the demonstrated benefits of OAC in
this group of patients, it was shown in RIKS-HIA
analysis (6,182 patients) that only 30% of patients
with indications were prescribed triple therapy. The
patients who received OAC were younger, had no
history of chronic pulmonary disease, and no de-
mentia, but were more likely to have a history of
stroke or coronary revascularization. Bundle-
branch block, ST-segment elevation, or T-wave in-
version on electrocardiogram had no effect on the
use of OAC. ACE inhibitors, beta-blockers, digita-
lis, and statins were administered significantly more
often to patients discharged with OAC [47].
The RICO Survey showed that, among patients
with STEMI who were receiving dual antiplatelet
therapy and OAC therapy, only 44% had an INR
value between 2 and 3. The OAC group had a hi-
gher Killip class and lower left ventricular ejection
fraction than the non-OAC group. The use of throm-
bolysis, heparin and antiplatelet drugs, and corona-
ry angiography performance were much reduced in
patients receiving OAC. The use of glycoprotein IIb/
/IIIa receptor antagonists did not differ between the
two groups. The incidence rates of ventricular arr-
hythmia, cardiogenic shock, and stroke were simi-
lar for both groups. Of interest, prior OAC treat-
ment was not an independent factor of major ble-
eding; advanced age and heart failure were shown
to be predictors of bleeding events in this cohort.
However, OAC was an independent predictor of in-
hospital heart failure, together with age, diabetes,
and low creatinine clearance rates [48].
Hemorrhagic complications
Hemorrhagic complications are the most com-
mon complications during treatment for ACS (exc-
luding ischemic events). When assessing the seve-
rity of bleeding, several clinical aspects should be
considered (localization and influence on hemody-
namic parameters), in addition to the need for blo-
od transfusion and reductions in hemoglobin levels
[49]. Bleeding can be classified as severe, life thre-
atening, moderate, or mild. However, the cutoff
values for these classifications can vary between
studies, making it difficult to compare the frequen-
cy of bleeding among such studies. Data from many
randomized trials show that frequency of these com-
plications ranges from < 2% in OASIS-2, PRISM,
and PURSUIT to > 8% in SYNERGY [50–52].
According to data from the European GRACE regi-
stry, which included 24,045 patients, the total fre-
quency of severe bleeding is 3.9% in STEMI pa-
tients, 4.7% in NSTE-ACS patients, and 2.3% in
unstable angina patients [53].
There are several independent prognostic factors
associated with serious bleeding, including advanced
age, female sex, history of prior bleeding, prior PCI,
renal failure, and use of glycoprotein IIb/IIIa recep-
tor antagonists. The risk of bleeding is also incre-
ased by administration of drugs at high doses that
are too high, especially in women, elderly indivi-
duals, or patients with renal failure [54]. The incre-
ase in bleeding risk with worsening renal function
shows a trend similar to the increase in risk of de-
ath in the GRACE registry, so physicians should be
cautious when selecting aggressive invasive, anti-
platelet, or antithrombotic treatment strategies in
high-risk patients [29].
The incidence of bleeding events is related to
the number and intensity of antiplatelet and anti-
thrombotic therapies. In the study by Flaker et al.
[55], the addition of ASA to warfarin treatment (with
INR value between 2 and 3) increased the number
of serious bleeding events (3.9% per year) in pa-
tients with AF compared with warfarin only (2.3%
per year). Triple therapy (ASA + clopidogrel +
+ warfarin) was associated with an increased risk
of serious bleeding by about 7% per year [56–60].
Bleeding events were reported in 3 patients rece-
iving ASA, clopidogrel, and OAC (18.8%) and in 1 pa-
tient receiving dual antiplatelet therapy (16.7%)
during a 30-day observation of 27 patients who had
undergone PCI and who had indications for chronic
anticoagulation [61]. However, another observation
of PCI patients who required anticoagulation therapy
showed that major bleeding events only occurred in
patients receiving triple therapy (6.6%): two cases of
gastrointestinal bleeding, four cases of nasal bleeding
requiring surgery or blood transfusion, and one death
caused by intracranial bleeding. Minor bleeding
events were also more common in patients rece-
iving triple therapy (14.9%) compared with those
receiving dual antiplatelet therapy (3.8%) [57].
Many researchers have pointed out that inci-
dence of bleeding depends on the antiplatelet drug
dose and accurate control of the INR value. Orford
et al. [59] conducted a retrospective study of 66 pa-
tients who were assigned triple therapy after PCI.
No incidents of stent thrombosis, MI, or death were
reported. Six patients suffered bleeding events, of
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which two ended spontaneously, two required blo-
od transfusion, and one occurred within 24 hours
of discharge (with INR = 1) and was attributed to
an interaction between ASA, clopidogrel, and eno-
xaparin. Although the incidence of bleeding com-
plications was higher with triple therapy (9.2%) as
compared to ASA and thienopyridine (1.8%) or ASA
and OAC (6.5%), inappropriate use of OAC therapy
was reported to be the main cause of increased risk
of bleeding events [7, 8, 25, 62]. Of note, all serio-
us bleeding events requiring intervention occurred
at an INR value significantly greater than the the-
rapeutic level [59]. Withdrawal of thienopyridine
owing to bleeding was associated with increased
risk of sudden death and MI during a 30-day obse-
rvation period [7, 8, 25, 62]. Buresly et al. [63] in-
vestigated different combinations of antiplatelet and
antithrombotic therapy in patients of advanced age
(aged > 65 years) who had suffered an MI. Bleeding
events occurred in 6.7% of patients, most of which
were gastrointestinal (particularly in patients rece-
iving antiplatelet drugs or ASA in combination with
warfarin). Intracranial bleeding was most common
in patients receiving ASA and warfarin. Dual anti-
platelet therapy was associated with an increased
risk of bleeding compared with ASA alone, but this
increased risk was still lower than with the combi-
nation of ASA and warfarin. Only one patient rece-
iving triple therapy suffered a bleeding event (he-
maturia).
Current recommendations related
to oral anticoagulation and
dual antiplatelet therapy (Table 1)
Venous thrombotic disease
Oral anticoagulants are the cornerstone of pre-
vention and treatment of VTD, including deep vein
thrombosis and pulmonary embolism. Anticoagulant
treatment should be administered for at least
3 months in cases of reversible or transient-factor-
caused prothrombotic conditions and 6 months in
cases of thrombosis of unknown reason (class I,
level of evidence A). Secondary prophylaxis in pa-
tients with malignant disease should be chronic or
administered until recovery (class I, level of eviden-
ce C). In cases of recurrence or thrombophilia, long-
-term treatment should be used (class I, level of
evidence C). It is reasonable to consider use of ace-
nocumarol as the primary prophylaxis in patients
with a particularly high risk of thrombosis after or-
thopedic or gynecologic surgery. It is not recom-
mended that antiplatelet therapy be administered
alone as prophylaxis or treatment of VTD [64].
Atrial fibrillation
AF is connected with increased risk of thrombo-
embolic complications, including ischemic stroke.
Anticoagulant therapy is recommended for most pa-
tients with AF. According to ESC/ACC/AHA guideli-
nes, strong indications for antithrombotic treatment
relate to patients with AF and one major or two mo-
derate thromboembolic risk factors (class I, level of
evidence A). Major risk factors include history of pre-
vious stroke, transient ischemic attack, cerebral em-
bolism, mitral stenosis, or prosthetic heart valve.
Moderate factors include age more than 75 years,
hypertension, heart failure, left ventricular ejection
fraction less than 35%, and diabetes. Antiplatelet the-
rapy with ASA is possible in cases of no or one mode-
rate risk factor (class I, level of evidence A) [65].
Prosthetic heart valves and
valvular heart diseases
Chronic anticoagulant therapy is recommended
in patients with mechanical prosthetic heart valves
(class I, level of evidence C). The intensity of treat-
ment depends on the type of valve, its localization,
and coexisting thromboembolic risk factors. If addi-
tional risk factors are present (such as AF, MI, enlar-
gement of the left atrium, low ejection fraction, or
systemic embolism despite therapeutic INR) addition
of ASA (75–100 mg/day) is recommended [66, 67].
Antithrombotic treatment is also recommended
for the first 3 months after insertion of a bioprosthe-
tic valve and for 3–12 months in patients with biopro-
sthetic valves who have a history of systemic embo-
lism. For patients in sinus rhythm but without AF,
long-term therapy with ASA is recommended [66, 67].
According to ESC/ACC/AHA guidelines, antico-
agulation therapy is indicated in patients with mitral
stenosis in sinus rhythm if they have a history of
a prior embolic event, left atrium thrombus (class 1,
level of evidence C), dense spontaneous contrast, or
a left atrial dimension greater than or equal to 50 mm
in echocardiography (class IIa, level of evidence C).
In patients with mitral regurgitation, anticoagulant
therapy should be administered to those with AF,
a history of systemic embolism, or evidence of atrial
thrombus, and during the first 3 months after mitral
valve repair (no classification for this recommenda-
tion). There is no evidence to support the use of ASA
as an alternative treatment in patients with heart
disease of the mitral valve [68, 69].
Other indications for
antithrombotic therapy
Nowadays, anticoagulants are indicated for pri-
mary pulmonary hypertension (class IIa, level of
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Table 1. Current recommendations for antithrombotic therapy.
Disease Indication for Recommended Class and Guidelines
antithrombotic therapy duration level of
of treatment evidence
Venous Reversible or transient factor 3 months I-A Guidelines for management
thrombotic causing a prothrombotic of patients with venous
disease condition thrombotic disease [64]
Thrombosis of unknown 6 months I-A
reason
Malignant disease Lifelong or I-C
until recovery
Recurrence of thrombosis Lifelong I-C
or thrombophilia
Atrial Presence of one major Lifelong I-A ACC/AHA/ESC 2006
fibrillation (previous stroke, TIA, cerebral Guidelines for the
embolism, mitral stenosis or management of patients
prosthetic heart valve) or at with atrial fibrillation [65]
least two moderate
(age > 75 years, hypertension,
HF, LVEF < 35%, diabetes)
thromboembolic risk/s factors
Mechanical All patients Lifelong I-C
prosthetic
heart valve
Bioprosthetic All patients 3 months I-C




after heart valve surgery,
ESC 2005 [67]
Mitral History of prior embolic event, Lifelong I-C ACC/AHA 2006 Guidelines
stenosis left atrial thrombus for the management of
Dense spontaneous contrast Lifelong IIa-C patients with valvular heart
or left atrial dimension greater disease: a report of American
than or equal to 50 mm in College of Cardiology/American
echocardiography Heart Association Task Force
Mitral History of systemic embolism Lifelong N/A
on Practice Guidelines [68]
regurgitation or evidence of atrial thrombus Guidelines on the management
of valvular heart disease:
After mitral valve repair 3 months N/A The Task Force on theManagement of Valvular Heart
Disease of the European
Society of Cardiology 2007 [69]
Primary All patients Lifelong IIa-C Guidelines on diagnosis
pulmonary and treatment of pulmonary
hypertension arterial hypertension
Secondary All patients Lifelong IIb-C The Task Force on Diagnosis and
pulmonary Treatment of Pulmonary Arterial
hypertension Hypertension of the European
Society of Cardiology 2004 [70]
Dissection of All patients 3–6 months, IIa-B Guidelines for prevention of
intracerebral as an alternative stroke in patients with ischemic
arteries, to antiplatelet stroke or transient ischemic
intracranial therapy attack: a statement for health-
vein care professionals from the
thrombosis AHA/American Stroke
Association Council
on Stroke 2006 [71]
TIA — transient ischemic attack, HF — heart failure, LVEF — left ventricular ejection fraction, N/A—not applicable
Antithrombotic
Therapy in Valvular Heart
Disease — Native and
Prosthetic: The Seventh
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evidence C) and permitted for secondary pulmona-
ry hypertension (class IIb, level of evidence C) [70].
American Heart Association/American Stroke
Association guidelines recommend the use of OAC
in the dissection of intracerebral arteries for 3–
–6 months as an alternative to antiplatelet drugs
(class IIa, level of evidence B) and for 3–6 months
in intracranial vein thrombosis (class IIa, level of
evidence B) [71].
Dual antiplatelet therapy (Table 2)
When BMSs are implanted, dual antiplatelet the-
rapy is recommended for 1 month and for at least
12 months if the patient has undergone DES interven-
tion (class I, level of evidence B) [28].
It is well established that patients with ACS
without ST elevation should receive concomitant
treatment with ASA and clopidogrel for 12 months,
independent of whether they are treated pharmaco-
logically or by PCI (class I, level of evidence B) [2].
The efficacy of this combination treatment is greater
than that of ASA alone or ASA and OAC [7, 8, 25, 62,
72–74]. According to ACC/AHA guidelines, the ma-
nagement of patients with ST elevation MI should
involve ASA and clopidogrel treatment independent
of use of fibrinolytic therapy (class I, level of evi-
dence A), for at least 14 days (class I, level of evi-
dence B). Long-term maintenance of dual therapy
(for about 1 year) is reasonable in STEMI patients
(new recommendation; class IIa, level of evidence C).
There are no specific recommendations regarding the
management of patients with STEMI who under-
went PCI, although according to the guidelines it
seems optimal to use this therapy for 12 months.
Triple therapy (Table 3)
ESC/AHA/ACC guidelines for the management
of patients receiving OAC treatment and presen-
ting with NSTE-ACS suggest suspension of antith-
rombotic treatment [such as unfractionated hepa-
rin, low-molecular-weight-heparin, fondaparinux or
bivalirudin] until the INR is < 2 during the acute
phase. With long-term treatment, it is recommen-
ded that the lowest therapeutic level of INR be
maintained, the shortest concomitant treatment
with clopidogrel and OAC, and precise control of
INR (class II, level of evidence C). However, treat-
ment decisions should be made on an individuali-
zed basis and should take into account the bleeding
and thromboembolic risks.
According to 2007 STEMI Focused Update Re-
commendations, for patients requiring warfarin, clopi-
dogrel, and ASA, an INR of 2–2.5 is recommended with
low-dose ASA (75–81 mg) and 75 mg clopidogrel.
ESC/AHA/ACC guidelines for the management
of patients with AF suggest that clopidogrel (75 mg)
Table 2. Current recommendations for dual antiplatelet therapy.
Indication for dual Recommended Class and level Guidelines
antiplatelet therapy duration of treatment of evidence
NSTE-ACS independent 12 months I-A ESC Guidelines for the
of the treatment diagnosis and treatment
approach of NSTE-ACS 2007 [2]
STEMI treated 12 months I-B 2007 Focused Update of the
with PCI and DES ACC/AHA 2004 Guidelines
STEMI treated For a minimum 1 month, I-B
for the management
with PCI and BMS 12 months is optimal
of patients with ST-elevation
myocardial infarction [1]
STEMI treated with Minimum 14 days I-B
PCI without stenting
or pharmacologically
STEMI treated with Lifelong (e.g. for 12 months) IIa-C
fibrinolysis or without
reperfusion
BMS implantation For a minimum of 1 month, I-B 2007 Focused Update of the
12 months is optimal ACC/AHA/SCAI 2005
DES implantation At least 12 months I-B Guideline Update for
percutaneous coronary
intervention: a report of
the ACC/AHA
Task Force on Practice
guidelines [28]
NSTE-ACS — non-ST-elevation acute coronary syndrome, STEMI — ST-elevation myocardial infarction, PCI — percutaneous coronary intervention,
DES — drug eluting stent, BMS — bare metal stent
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and warfarin (INR 2–3) should be administered for
9–12 months as supportive treatment in patients
with ACS. If no recurrent ischemic event occurs,
the patient can continue with warfarin monothera-
py (no classification for this recommendation) [65].
On the other hand, the earliest guidelines of
the American College of Chest Physicians for anti-
thrombotic therapy recommend the administration
of ASA and OAC (with INR 2–3) for at least 3 mon-
ths in patients after MI at high risk of thromboem-
bolic events (such as those with AF, history of prior
VTD) [75]. However, patients treated with PCI
should receive triple therapy but with frequent con-
trol of INR to maintain the index at its lowest the-
rapeutic level. Use of proton-pump inhibitors can
be considered when the risk of gastrointestinal ble-
eding is increased. Further data are needed to de-
termine if vitamin K supplementation is beneficial
for the stabilization of INR. When choosing the type
of stent in patients with indications for long-term
anticoagulation it is better to use BMS, which allows
the duration of triple therapy to be reduced to 4 we-
eks, followed by treatment with ASA and OAC [75].
The indications for triple therapy mentioned in
the ESC guidelines for management of patients after
valvular surgery include: coexistence of arterial
disease, previous coronary stenting, recurrent
embolism, but only when followed by full diagno-
stics, correction of risk factors and antithrombotic
treatment when recurrent incidents could not be
prevented; and in patients with ball valves, in whom
dipyridamole should be the first choice of treatment.
Table 3. Recommendations for concomitant dual antiplatelet and antithrombotic treatment in patients
with indications for triple therapy.
Guidelines Recommendations Class and level
of evidence
ESC Guidelines for the 1. Suspension of antithrombotic treatment until INR Lack
diagnosis and treatment is < 2 during the acute phase
of non-ST-segment 2. As long-term maintenance treatment with the lowest II-C
elevation acute coronary therapeutic level of INR, the shortest period of
syndrome 2007 concomitant treatment with clopidogrel and OAC,
and precise control of INR
2007 Focused Update In patients requiring warfarin, clopidogrel, and ASA I-C
of the ACC/AHA 2004 maintenance with INR 2–2,5; low dose ASA (75–81 mg)




ACC/AHA/ESC 2006 In patients with ACS use of clopidogrel (75 mg) together Lack
Guidelines for the with warfarin (INR 2–3) for 9–12 months as supportive
management of patients treatment, if no recurrent ischemic event occurs,
with atrial fibrillation continue with warfarin alone
Antithrombotic and 1. Use of ASA and OAC (with INR of 2–3) for at least 3 months II-A
thrombolytic therapy. in patients after MI and at high risk of thromboembolic
The primary and secondary events (such as AF, history of prior VTD)
prevention of coronary 2. Patients treated with PCI should receive triple therapy II-C
artery disease: American but the need for frequent control of INR to maintain
College of Chest Physicians the index at the lowest therapeutic level is crucial;
Evidence-Based Clinical use of proton-pump inhibitors can be considered
Practice Guidelines when risk of gastrointestinal bleeding is increased
(8th Edition) 2008
Recommendations for the Relative indications for triple therapy in patients who Lack
management of patients have undergone valvular surgery include:
after heart valve surgery 1. coexistence of arterial disease
ESC 2005 2. condition after coronary stenting
3. recurrent embolism, but only if followed by full diagnostics,
correction of risk factors, and antithrombotic treatment, and
when recurrent incidents could not be prevented
4. in patients with ball valve, dipyridamole should
be the first choice of treatment
OAC — oral anticoagulant, ACS — acute coronary syndrome, MI — myocardial infarction, AF — atrial fibrillation, VTD — venous thrombotic disease,
ASA — acetylsalicylic acid, INR — international normalized ratio
187
Leszek Bryniarski et al., Dual antiplatelet therapy and antithrombotic treatment
www.cardiologyjournal.org
Contraindications for triple therapy include: histo-
ry of gastrointestinal bleeding and current chronic
peptic ulcer disease or angiodysplasia, increased
reaction after ASA administration with prolonged
bleeding time, uncontrolled hypertension due to
risk of intracranial bleeding and ineffectiveness of
ASA in prophylaxis of stroke in hypertensive patients,
advanced age, especially women aged > 75 years,
concomitant administration of many drugs simultane-
ously or antibiotics, or significant fluctuations in INR
value despite attempts to control it [67].
Summary
Most recent trials and meta-analyses support
the administration of long-term treatment with OAC
in patients with AF and indications for dual antipla-
telet therapy (such as prior MI or PCI). Therapeu-
tic decisions should be made after individualized
assessment of bleeding risk and the risks of throm-
boembolic events and stent thrombosis. Patients
with AF and one major or at least two moderate
factors of thromboembolic risk should receive an-
tithrombotic treatment with maintenance of INR
within the therapeutic level. Excluding patients with
a high risk of bleeding, triple therapy consisting of
ASA, clopidogrel, and OAC seems the most benefi-
cial treatment strategy. If a patient receiving OAC
requires coronary stenting, it is better to use BMS
than DES because the former allows the duration of
dual antiplatelet therapy to be reduced. Further trials
are required to determine the optimal therapeutic
strategy and control in these patients.
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